FIND

researchers

DISCOVER

relevant articles

PROMOTE

your research

now for free

Albert Abad

Research Profile

Chemicals & Drugs

Disorders

Procedures

Antineoplastic Combined Chemotherapy Protocols

Physiology

Concepts & Ideas

Co-author Network

Publications

TOP 3
Javier Sastre; Josep M Tabernero; Manuel Valladares; Marta Vidaurreta; Albert Abad; Enrique Aranda; Antonio Arrivi; Manuel Benavides; Carlos Fernández-Martos; Manuel Gallén; Auxiliadora Gómez España; Encarnación González; M Luisa Maestro; Eugenio Marcuello; Bartomeu Massuti; Fernando Rivera; Eduardo Díaz-Rubio
Circulating tumor cell count is a prognostic factor in metastatic colorectal cancer patients receiving first-line chemotherapy plus bevacizumab: a Spanish Cooperative Group for the Treatment of Digestive Tumors study.
Eduardo Díaz-Rubio; Rosario Dueñas; Pilar Escudero; Carlos Fernández-Martos; Manuel Gallén; Auxiliadora Gómez España; Encarnación González; Adelaida Lacasta; Marta Llanos; Amelia López-Ladrón; Ferrán Losa; Eugenio Marcuello; Purificación Martínez de Prado; Bartomeu Massutí; Fernando Rivera; Maria J Safont; Javier Sastre; Josep Tabernero; Manuel Valladares; Albert Abad; Antonio Antón; Enrique Aranda; Antonio Arrivi; Manuel Benavides; Andrés Cervantes
First-line XELOX plus bevacizumab followed by XELOX plus bevacizumab or single-agent bevacizumab as maintenance therapy in patients with metastatic colorectal cancer: the phase III MACRO TTD study.
Eva Martinez-Balibrea; Albert Abad; A Martínez-Cardús; A Ginés; M Valladares; M Navarro; Enrique Aranda; E Marcuello; M Benavides; B Massutí; A Carrato; L Layos; Jose Luis Manzano; V Moreno
UGT1A and TYMS genetic variants predict toxicity and response of colorectal cancer patients treated with first-line irinotecan and fluorouracil combination therapy.

Register for free to view:

Visualized networks:

See your personal network in
sophisticated graphical views

GeoTargeted Searches:

Locate experts around the world
and connect with global collaborators

Research Profiles:

See the research activity
of experts around the globe

Geonetwork of Albert Abad (preview)

Cities where this author has publications
Cities where co-authors of this author have publications

Flash Player Required

All Publications

2012: Javier Sastre; Josep M Tabernero; Manuel Valladares; Marta Vidaurreta; Albert Abad; Enrique Aranda; Antonio Arrivi; Manuel Benavides; Carlos Fernández-Martos; Manuel Gallén; Auxiliadora Gómez España; Encarnación González; M Luisa Maestro; Eugenio Marcuello; Bartomeu Massuti; Fernando Rivera; Eduardo Díaz-Rubio
Circulating tumor cell count is a prognostic factor in metastatic colorectal cancer patients receiving first-line chemotherapy plus bevacizumab: a Spanish Cooperative Group for the Treatment of Digestive Tumors study.
The oncologist 2012;17(7):947-55.
2012: Eduardo Díaz-Rubio; Rosario Dueñas; Pilar Escudero; Carlos Fernández-Martos; Manuel Gallén; Auxiliadora Gómez España; Encarnación González; Adelaida Lacasta; Marta Llanos; Amelia López-Ladrón; Ferrán Losa; Eugenio Marcuello; Purificación Martínez de Prado; Bartomeu Massutí; Fernando Rivera; Maria J Safont; Javier Sastre; Josep Tabernero; Manuel Valladares; Albert Abad; Antonio Antón; Enrique Aranda; Antonio Arrivi; Manuel Benavides; Andrés Cervantes
First-line XELOX plus bevacizumab followed by XELOX plus bevacizumab or single-agent bevacizumab as maintenance therapy in patients with metastatic colorectal cancer: the phase III MACRO TTD study.
The oncologist 2012;17(1):15-25.
2010: Eva Martinez-Balibrea; Albert Abad; A Martínez-Cardús; A Ginés; M Valladares; M Navarro; Enrique Aranda; E Marcuello; M Benavides; B Massutí; A Carrato; L Layos; Jose Luis Manzano; V Moreno
UGT1A and TYMS genetic variants predict toxicity and response of colorectal cancer patients treated with first-line irinotecan and fluorouracil combination therapy.
British journal of cancer 2010;103(4):581-9.
2009: Eva Martinez-Balibrea; Anna Martínez-Cardús; Eva Musulén; Alba Ginés; José Luis Manzano; Enrique Aranda; Carmen Plasencia; Nouri Neamati; Albert Abad
Increased levels of copper efflux transporter ATP7B are associated with poor outcome in colorectal cancer patients receiving oxaliplatin-based chemotherapy.
International journal of cancer. Journal international du cancer 2009;124(12):2905-10.
2009: Javier Sastre; Enrique Aranda; Bartomeu Massutí; Josep Tabernero; Manuel Chaves; Albert Abad; Alfredo Carrato; Juan José Reina; Bernardo Queralt; Auxiliadora Gómez España; Encarnación González-Flores; Fernando Rivera; Ferrán Losa; Teresa García; Pedro Sanchez-Rovira; Inmaculada Maestu; Eduardo Díaz-Rubio
Elderly patients with advanced colorectal cancer derive similar benefit without excessive toxicity after first-line chemotherapy with oxaliplatin-based combinations: comparative outcomes from the 03-TTD-01 phase III study.
Critical reviews in oncology/hematology 2009;70(2):134-44.
2009: Eva Martinez-Balibrea; Carmen Plasencia; Alba Ginés; Anna Martinez-Cardús; Eva Musulén; Rodrigo Aguilera; José Luis Manzano; Nouri Neamati; Albert Abad
A proteomic approach links decreased pyruvate kinase M2 expression to oxaliplatin resistance in patients with colorectal cancer and in human cell lines.
Molecular cancer therapeutics 2009;8(4):771-8.
2009: Anna Martinez-Cardús; Eva Martinez-Balibrea; Eva Bandrés; Raquel Malumbres; Alba Ginés; José Luís Manzano; Miquel Taron; Jesús Garcia-Foncillas; Albert Abad
Pharmacogenomic approach for the identification of novel determinants of acquired resistance to oxaliplatin in colorectal cancer.
Molecular cancer therapeutics 2009;8(1):194-202.
2008: Eva Martinez-Balibrea; Albert Abad; Enrique Aranda; Javier Sastre; Jose Luis Manzano; Eduardo Díaz-Rubio; Auxiliadora Gómez España; Jorge Aparicio; Teresa García; Inmaculada Maestu; Anna Martínez-Cardús; Alba Ginés; Elisabet Guino
Pharmacogenetic approach for capecitabine or 5-fluorouracil selection to be combined with oxaliplatin as first-line chemotherapy in advanced colorectal cancer.
European journal of cancer (Oxford, England : 1990) 2008;44(9):1229-37.
2007: Albert Abad; José Luis Manzano; Cristina Martí
Reflections on adjuvant treatment of gastric cancer.
Therapeutics and clinical risk management 2007;3(4):563-7.
2007: Albert Font; A Arellano; Jaume Fernández-Llamazares; D Casas; J Boix; J Cardenal; Mireia Margelí; Jose Luis Manzano; Albert Abad; Rafael Rosell
Weekly docetaxel with concomitant radiotherapy in patients with inoperable oesophageal cancer.
Clinical & translational oncology : official publication of the Federation of Spanish Oncology Societies and of the National Cancer Institute of Mexico 2007;9(3):177-82.
2007: Eva Martinez-Balibrea; Jose Luis Manzano; Anna Martinez-Cardus; Teresa Moran; Beatriz Cirauqui; Silvia Catot; Miquel Taron; Albert Abad
Combined analysis of genetic polymorphisms in thymidylate synthase, uridine diphosphate glucoronosyltransferase and X-ray cross complementing factor 1 genes as a prognostic factor in advanced colorectal cancer patients treated with 5-fluorouracil plus oxaliplatin or irinotecan.
Oncology reports 2007;17(3):637-45.
2006: Carmen Plasencia; E Martínez-Balibrea; A Martinez-Cardús; David I Quinn; Albert Abad; Nouri Neamati
Expression analysis of genes involved in oxaliplatin response and development of oxaliplatin-resistant HT29 colon cancer cells.
International journal of oncology 2006;29(1):225-35.
2005: Carmen Plasencia; Albert Abad
[Colorectal cancer and microsatellite instability].
Medicina clínica 2005;124(12):454-6.
2004: Carmen Plasencia; Albert Abad; Eva Martinez-Balibrea; Miquel Taron
Antiproliferative effects of ZD0473 (AMD473) in combination with 5-fluorouracil or SN38 in human colorectal cancer cell lines.
Investigational new drugs 2004;22(4):399-409.
2003: Albert Font; José Miguel Sánchez; Miquel Tarón; Eva Martinez-Balibrea; José Javier Sánchez; Jose Luis Manzano; Mireia Margelí; Martin Richardet; Agustí Barnadas; Albert Abad; Rafael Rosell
Weekly regimen of irinotecan/docetaxel in previously treated non-small cell lung cancer patients and correlation with uridine diphosphate glucuronosyltransferase 1A1 (UGT1A1) polymorphism.
Investigational new drugs 2003;21(4):435-43.
2003: C Balaña; Jose Luis Manzano; I Moreno; Beatriz Cirauqui; Albert Abad; Albert Font; José-Luis Mate; Rafael Rosell
A phase II study of cisplatin, etoposide and gemcitabine in an unfavourable group of patients with carcinoma of unknown primary site.
Annals of oncology : official journal of the European Society for Medical Oncology / ESMO 2003;14(9):1425-9.
2003: Carmen Plasencia; P H Rooney; Miquel Taron; Eva Martinez-Balibrea; howard mcleod; Albert Abad
Chromosomal imbalance maps of human 5FU-resistant colorectal cancer cell lines: implications in the analysis of 5FU-acquired resistance mechanisms.
International journal of oncology 2003;22(5):945-53.
2002: Carme Sarries; Eric Haura; Barbara Roig; Miquel Taron; Albert Abad; Giorgio V Scagliotti; Rafael Rosell
Pharmacogenomic strategies for developing customized chemotherapy in non-small cell lung cancer.
Pharmacogenomics 2002;3(6):763-80.
2002: Albert Font; Jose Miguel Sanchez; Rafael Rosell; Miquel Taron; E Martinez; Mónica Guillot; Jose Luis Manzano; M Margeli; Agustí Barnadas; Albert Abad
Phase I study of weekly CPT-11 (irinotecan)/docetaxel in patients with advanced solid tumors.
Lung cancer (Amsterdam, Netherlands) 2002;37(2):213-8.
2000: Miquel Taron; Carmen Plasencia; Albert Abad; C Martin; Mónica Guillot
Cytotoxic effects of topotecan combined with various active G2/M-phase anticancer drugs in human tumor-derived cell lines.
Investigational new drugs 2000;18(2):139-47.
1999: Rafael Rosell; J Gómez-Codina; Carlos Camps; J Javier Sánchez; Jose Maestre; J Padilla; A Cantó; Albert Abad; J Roig
Preresectional chemotherapy in stage IIIA non-small-cell lung cancer: a 7-year assessment of a randomized controlled trial.
Lung cancer (Amsterdam, Netherlands) 1999;26(1):7-14.